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Background
HIV-1 is still a major public health problem and one of
the priorities of the World Health Organization. The
development of HAART against HIV was a considerable
advance for infected individuals, but this life-long treat-
ment does only block virus replication, and no viral era-
dication is obtained. Furthermore, HAART may exhibit
long-term toxicity and may eventually lead to the emer-
gence of drug-resistant viral variants. We explore a new
durable therapeutic intervention based on a gene ther-
apy that induces RNA interference (RNAi) against HIV-
1. In this pre-clinical research setting, “humanized”
experimental mouse models are of interest considering
the relative ease of handling and relatively low cost as
compared to non-human primates.
Methods
We have developed an RNAi gene therapy based on the
transduction of human hematopoietic progenitor cells
(HPC) with lentiviral vectors encoding short-hairpin
RNAs to induce silencing of HIV genes. We have tested
the efficacy and safety of such a shRNA-based gene
therapy strategy in the “Human Immune System” (HIS)
BALB/c Rag2
-/-IL-2Rgc
-/- mouse model, which are
reconstituted with human HPC that were first trans-
duced ex vivo with a lentiviral vector expressing the
antiviral shRNAs.
Results
We observed a normal in vivo development of the
human immune system with a good recovery of human
shRNA+cells for the candidate shPol47, shPol1 and
shRT5 inhibitors. However, the in vivo recovery of
human shGag5-transduced cells was extremely poor,
suggesting a negative impact of this specific shRNA on
the development of the human immune system. When
t h e s e4s h R N A sw e r ec o m b i n e di nas i n g l el e n t i v i r a l
vector (R4), we observed a similar negative off-target
effect due to the shGag5 component. Upon removal of
shGag5 as in vector R3, transduction of human HPC
results in a normal differentiation of the human immune
system, highlighting the in vivo safety of this candidate
R3 gene therapy vector for a clinical trial. Moreover,
human HPC expressing the antiviral shNef generate
human CD4+T cells with the ability to resist HIV-1
replication in a sequence specific manner.
Conclusion
Overall, these results underscore the usefulness of the
HIS (BALB-Rag/g) mouse model for testing the safety
and efficacy of durable anti-HIV gene therapy
approaches. In this model, human HPC expressing anti-
HIV-1 shRNA give rise to multi-lineage reconstitution
of the immune system in vivo and generate CD4
+ T
cells that are not susceptible for HIV-1 replication.
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